Artwork

コンテンツは TTP plc によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、TTP plc またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal
Player FM -ポッドキャストアプリ
Player FMアプリでオフラインにしPlayer FMう!

Life Science Investment: How to invest in change

44:24
 
シェア
 

Manage episode 334805771 series 2994360
コンテンツは TTP plc によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、TTP plc またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Gonzalo Garcia
Gonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.
https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=uk

Dr. Jason Mellad
Jason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.
https://www.linkedin.com/in/jason-mellad-54890622/

The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

  continue reading

20 つのエピソード

Artwork
iconシェア
 
Manage episode 334805771 series 2994360
コンテンツは TTP plc によって提供されます。エピソード、グラフィック、ポッドキャストの説明を含むすべてのポッドキャスト コンテンツは、TTP plc またはそのポッドキャスト プラットフォーム パートナーによって直接アップロードされ、提供されます。誰かがあなたの著作権で保護された作品をあなたの許可なく使用していると思われる場合は、ここで概説されているプロセスに従うことができますhttps://ja.player.fm/legal

The pandemic drastically altered the landscape for investment flowing into the Life Sciences. Not only was there more money going in, but the market needs changed too, with an unprecedented focus on scaling sectors like testing and vaccines. But what did this mean for sectors which were not on the Covid front line? What happened to the trends that were in train before the pandemic hit? And what have we learnt from this experience that we can deploy in the face of the next global challenge? In this episode of Invent: Life Sciences, we look at the past, present and future of investing in the sector, to explore the profound effects that the pandemic has had on it as a whole - and find that, when we pull together, amazing things can happen.

Find out more on this week's episode of Invent: Life Sciences from TTP.

This Week's Guests

Dr. Gonzalo Garcia
Gonzalo Garcia is a Biotech investor, company builder and partner at Syncona limited. Syncona are a company who found, build and fund early stage companies to turn science into transformational treatments, in fields ranging from cell and gene, to biologics and small molecule. Prior to this, Gonzalo completed a PhD in Protein Biophysics from the University of Cambridge, an EMBO Short Term Fellowship in Cell Biology at Harvard Medical School, and was a project leader at Boston Consulting Group. His work at Syncona includes his role as Chief of Staff and Board observer at Resolution Therapeutics.
https://www.linkedin.com/in/gonzaloagarciag/?originalSubdomain=uk

Dr. Jason Mellad
Jason Mellad is the CEO and co-founder of Start Codon. After a phd in medicine from the University of Cambridge, Jason worked in various directing roles for a number of exciting Life Sciences companies, like Cambridge Epigenetics, before founding Start Codon in late 2018. Start Codon are a venture capital investor and venture builder who support aspiring entrepreneurs in development and commercialisation of their businesses. They look for the most disruptive innovations in the life sciences space, and have already seen dozens of successful start ups come through their programme to bring their ideas to the world.
https://www.linkedin.com/in/jason-mellad-54890622/

The Technology Partnership is where scientists & engineers develop new products & technologies that bring innovation & value to clients.
Find out more about our work here: https://www.ttp.com/

  continue reading

20 つのエピソード

すべてのエピソード

×
 
Loading …

プレーヤーFMへようこそ!

Player FMは今からすぐに楽しめるために高品質のポッドキャストをウェブでスキャンしています。 これは最高のポッドキャストアプリで、Android、iPhone、そしてWebで動作します。 全ての端末で購読を同期するためにサインアップしてください。

 

クイックリファレンスガイド